{
    "code": "02025781",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=02025781",
    "time": "2021-10-15 03:21:05",
    "許可證字號": "衛署藥輸字第025781號",
    "註銷狀態": "",
    "註銷日期": "",
    "註銷理由": "",
    "製造許可登錄編號": "",
    "有效日期": "111\/07\/31",
    "發證日期": "101\/07\/31",
    "許可證種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原登錄字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA00202578106",
    "中文品名": "&quot;德國&quot;委丹扎注射劑",
    "英文品名": "Vidaza Powder for Suspension for Injection",
    "適應症": "治療骨髓增生不良症候群高危險性的病人 (High Risk MDS)：頑固性貧血併有過量芽細胞 (RA with excess blasts, RAEB)、轉變中的頑固性貧血併有過量芽細胞 (RAEB in transformation, RAEB-T)、及慢性骨髓單核細胞性白血病 (chronic myelomonocytic leukemia, CMMoL)。\r\nVidaza適用於治療65歲（含）以上、不適合接受HSCT或密集化學治療、且骨髓芽細胞比例>30%的AML成人病人（依據WHO分類）。",
    "劑型": "243凍晶注射劑",
    "包裝": "100毫克玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "AZACITIDINE",
    "限制項目": "02輸　入 25監視中學名藥 5E已執行國內臨床試驗",
    "申請商名稱": "620117G076  賽基有限公司",
    "申請商地址": "臺北市松山區健康路156號5樓",
    "主製造廠": [
        {
            "": "GERMANY",
            "製程": ""
        }
    ],
    "次製造廠": [
        {
            "製造廠名稱": "FSG0036000  BOLLORE LOGISTICS SINGAPORE PTE. LTD.",
            "製造廠廠址": "101 ALPS AVENUE #03-01 SINGAPORE 498793",
            "製造廠公司地址": "",
            "製造廠國別": "SINGAPORE",
            "製程": "貼標廠"
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1008400500",
            "成分名稱": "AZACITIDINE",
            "含量描述": "",
            "含量": "100.0000000000",
            "單位": "MG"
        }
    ],
    "藥物辨識詳細資料": {
        "外觀尺寸": "28 x 50 (+\/-1) mm 小瓶裝",
        "特殊劑型": "",
        "顏色": "白色",
        "特殊氣味": "",
        "刻痕": "",
        "形狀": "",
        "標記一": "",
        "標記二": ""
    },
    "藥物辨識外觀圖片": [
        {
            "title": "Vidaza_Vial_2-107-03-19(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025781&Seq=001&Type=10"
        }
    ],
    "仿單外盒": [
        {
            "title": "2. Vidaza Chinese PIL_v4 Final (TFDA clean)_edit 20201203_PT 16Dec2020 TL_20210603-110-07-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025781&Seq=006&Type=9"
        },
        {
            "title": "3.2 Label-AZA1000TWVLØØØØV01H05_0528-110-07-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025781&Seq=007&Type=8"
        },
        {
            "title": "3.1 Box-AZA1000TWFBØØØØV01H06_0528-110-07-12.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=02025781&Seq=006&Type=8"
        }
    ]
}